Brief: Pharnext Says FDA Recommends To Conduct Additional Phase 3 Study To Evaluate PXT3003

Pharnext SCA

30/08/2019 07:14

Aug 30 (Reuters) - PHARNEXT SA  PHARN.PA :
    * PHARNEXT PROVIDES U.S. REGULATORY UPDATE ON PLEODRUG(TM)
PXT3003
IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
    * FDA RECOMMENDS THAT COMPANY CONDUCT AN ADDITIONAL PHASE 3
STUDY
TO EVALUATE PXT3003 IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A

Source text for Eikon:  ID:nEQ4PTfkfa 
Further company coverage:  PHARN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))